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Key points:  
• Little is known about the effect of prenatal exposure to non-steroidal anti-inflammatory 
drugs (NSAIDs) on child development.  
• It is important to address sources of potential confounding in pharmacoepidemiologic 
studies that investigate prenatal drug exposure and subsequent child development.  
• This study investigated sources of confounding by controlling for several potential 
confounders, using outcomes measured repeatedly and across different informants, 
studying pre-pregnancy exposure, and using proposed negative outcomes.  
• The association of prenatal exposure to NSAIDs and child attention problems is possibly 
partly explained by residual confounding by indication and measurement-related biases.  
• Future studies may consider using more objective measurements of outcomes alongside 
richer assessments of women’s decisions to use NSAIDs prior to and during pregnancy. 
 
Word count main text: 3348 
Word count Abstract: 250 words 
 
Prior postings and presentations: This work has not been presented or printed elsewhere.  
 
3 
 
Abstract 
Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used during 
pregnancy. Findings that prenatal NSAID exposure may affect offspring neurodevelopment have 
been inconsistent. We investigated the effect of prenatal NSAID exposure on childhood 
neurodevelopment, and explored the susceptibility of our effect estimates to forms of bias via 
negative exposure, negative outcome, and multi-informant analyses. 
Methods: In a cohort of pregnant women (n=6876), perinatal NSAID use was assessed by 
prescriptions and self-report. Primary neurodevelopmental outcomes included attention problems 
using maternal reports at 1½, 3 and 5 years. To explore potential systematic biases, we compared 
estimates from maternally reported attention problems to a teacher’s report and a measure of 
nonverbal intelligence assessed at a clinic visit at age 6 years; we also used NSAID use before 
pregnancy and somatic problems as a “negative” exposure and outcome, respectively. 
Results: Maternal reports suggested that prenatal exposure to NSAIDs was associated with more 
attention problems at younger ages (e.g., at age 3: mean difference in attention problems score: 
0.30; 95% CI 0.12, 0.48). However, no strong association with attention problems was found in 
the teacher report, and a similarly strong association between prenatal NSAID exposure and 
somatic complaints suggests residual confounding by indication likely remains. Moreover, 
prenatal exposure to NSAIDs was not associated with an observed measure of IQ (mean 
difference in IQ score: -0.32; 95% CI: -1.82, 1.19). 
Conclusions: Jointly, our results suggest that the observed associations between prenatal 
exposure to NSAIDs and child attention problems reflect systematic biases of a null or small 
effect. 
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Introduction 
Medication use during pregnancy is common. 1 One of the most frequently prescribed 
medications during pregnancy is non-steroidal anti-inflammatory drugs (NSAIDs). 2-6 Over-the-
counter use of NSAIDs is widespread, especially during the first trimester of pregnancy. 7,8 As 
medication use during pregnancy may pose a risk to the mother and her developing fetus, the 
potential benefits of the medication must be weighed against the risks for both mother and child. 
Therefore, information to guide patients and physicians to make a well-informed decision for the 
appropriate treatment during pregnancy is needed. 
NSAIDs, for example ibuprofen, naproxen, diclofenac and aspirin (acetylsalicylic acid), 9 
are widely recognized for their analgesic, antipyretic, and anti-inflammatory effects. 10 The 
action of NSAIDs results from cyclooxygenase (COX) inhibition, followed by suppression of 
prostaglandins-synthesis in the brain. 11 Based on animal studies, COX-2 has been shown to be 
present in the brain and seems to play an essential role in neurodevelopment. 12,13 Thus, a key 
question is whether prenatal NSAID use has effects on foetal brain development. 
Earlier research examining the association between prenatal exposure to NSAIDs and 
cognitive impairment in children has been inconsistent, with studies finding negative 14 and 
positive 15 associations with intelligence measures and cognitive functioning. For behavioural 
outcomes such as Attention Deficit Hyperactivity Disorder (ADHD) and attention problems, 
results have likewise been inconsistent. One animal study reported a protective effect on the risk 
of behavioural difficulties and hyperactivity. 16 In epidemiologic studies, some studies have 
found no association 17 while others have reported higher risks of attention problems among 
children exposed to NSAIDs in utero. 14  
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Discrepancies in previous research may be explained by: small sample sizes; differences 
in study populations (e.g. one study restricted to children born preterm 17); and differing 
susceptibilities to biases such as residual confounding by indication, 18 and artefacts of the study 
design (e.g., retrospective versus prospective 14 studies), or available measures for medication 
use (e.g., self-report versus prescription) or outcome (e.g., parent report versus other informants). 
In the absence of randomized trials, a crucial challenge faced by all these studies is disentangling 
the neurodevelopmental consequences of prenatal NSAIDs exposure from the effects of the 
underlying indication for drug use (i.e., confounding by indication). 19 Unlike more specialized 
prescription drugs with well-defined indications for use, analgesics are used for a wide range of 
indications. 18 Hence, confounders can be especially difficult to define, measure and 
appropriately adjust for.  
The aim of the current study is to investigate the effect of prenatal exposure to NSAIDs 
and neurodevelopment of children. We begin by estimating effects on neurodevelopmental 
outcomes while adjusting for many sources of potential confounding. To explore possible 
systematic biases to our estimates and prior studies’ estimates, we compared our estimates from 
maternally-reported outcomes to a teacher’s report, and further used NSAID use before 
pregnancy and somatic problems as a “negative” exposure and outcome, respectively.20 
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Methods 
Study design and Participants 
This study was embedded in the Generation R Study, a population-based prospective cohort from 
foetal life onwards. 21,22 Briefly, all pregnant women living in Rotterdam, the Netherlands, with 
an expected delivery date between April 2002 and January 2006 were invited to participate. The 
overall response rate based on the number of children born in Rotterdam in the same period was 
61%.23 The study was conducted in accordance with the guidelines of the World Medical 
Association Declaration of Helsinki and was approved by the Medical Ethics Committee of the 
Erasmus Medical Center, Rotterdam. Written informed consent was obtained from all 
participants. 
In total, 8237 children in the pre- and postnatal follow-up period were eligible. Those 
with missing or incomplete data on prenatal NSAID exposure were excluded (N=716). Of the 
remaining 7521 mother–child dyads with baseline data, 645 participants did not have 
information on cognitive, emotional or behavioural functioning (of at least one assessment) and 
were therefore excluded, yielding a final study sample size of 6876 (91.4%) children and 
mothers. The number of children varies slightly per analyses (Supplementary Figure S1). 
Measurements 
Prenatal NSAID exposure 
NSAID use during pregnancy was assessed via both self-report and prescription records. In each 
trimester, pregnant mothers reported in questionnaires whether they had used any medication. In 
the first trimester, the mothers were asked whether they used medications within the past 6 
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months. The mothers filled out the type of medication and when it was used (during pregnancy, 
only before pregnancy, or stopped when I knew I was pregnant). In the second and third 
trimesters, we asked which medications were used in the preceding 3 months. From these 
questionnaires, we assessed NSAIDs exposure and timing (before or during pregnancy). One 
question with several open text fields was used and thus information was not systematically 
collected. Further, no additional methods were used to enhance medication recall during 
pregnancy.   
We asked women for permission to contact their pharmacy to obtain information on filled 
prescriptions. For the large majority, permission was obtained and data were requested, but 
prescription records were only available in 60.2% (n=4142) of our study sample due to a delay in 
linkage (this specific data collection started later and could not be retrieved in all participants). 
The records screened for NSAIDs use provided information on the type of NSAIDs, duration, 
and dose. The agreement between self-reports and prescription records was 64.8%; the majority 
of disagreements were women who self-reported use while having no filled prescription, which 
we interpreted as likely indicating over-the-counter use. Based on either the prescription or self-
reported measures indicating use, there were 5117 (74.4%) women who did not use NSAIDs 
before or during pregnancy, 1286 (18.7%) with NSAID use before but not during pregnancy, and 
473 (6.9%) with NSAID use during pregnancy.  
 
Behavioural and emotional problems  
At the age of 1½, 3 and 5 year, child problem behaviour was assessed using the Dutch version of 
the Child Behavior Checklist for ages 1½ - 5 years (CBCL/1½ -5). 24 The CBCL/1½ -5 is a 99-
item parent report on problem behaviours with well-established psychometric properties. 25 The 
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Dutch version of the CBCL/1½ -5 is reliable and well validated, 26 and the subscales had a good 
fit in 23 international studies across diverse societies.  27 
The current study focused on the CBCL subscales for attention problems and somatic 
complaints. The CBCL has good reliability and validity; the internal consistency of the attention 
problems and somatic complaints scale, measured by Cronbach’s alpha was 0.68 and 0.80.  24 
Attention problems were also rated by teachers using the Teacher’s Report Form (TRF) 25 when 
the children were aged 6 years. Although 40% of children were 6 years or older at the time of 
assessment, we used the CBCL 1.5–5 (preschool version) for reasons of continuity.  
 
Nonverbal intelligence 
We used the Snijders–Oomen Non-verbal Intelligence Test 2.5-7-Revised (SON-R 2.5-7), 28 a 
reliable and valid measure. 28-30 Two subtests of the SON-R 2.5-7 were administered in 
Generation R at age 6 years: Mosaics, assessing spatial visualization abilities, and Categories, 
assessing abstract reasoning abilities. A scaled total score can be calculated for any combination 
of subtests with the same distribution characteristics as the IQ score. A correlation of r=0.86 was 
found between the score derived from the Mosaics and Categories subsets, and the IQ scores 
derived from the complete test. 28 The raw scores of each subtest were standardized; the sum of 
the standardized scores were converted into SON-R IQ score using age-specific reference scores 
provided in the manual (mean=100, SD=15). The average reliability of the SON-R 2½ 7 IQ 
score is 0.90, range 0.86–0.92 for the respective age. 28 The reliability of the subtests that were 
used in our study is: 0.73 for mosaics and 0.71 for categories. We chose a validated Dutch 
instrument and specifically investigated non-verbal IQ, because our sample is multi-ethnic 
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(differences in exposure to the Dutch language in young children could be present), and 
bilingualism is common. 
 
Covariates 
Potential confounders were selected based on the previous literature. 14-17,31,32 Information on 
gender, birth weight, and Apgar score at 5 min after birth were obtained from hospital records. 
Gestational age was obtained by foetal ultrasound examination. Maternal body mass index was 
determined by weight and height at the first visit. Maternal age, ethnicity and education were 
assessed by questionnaires. Ethnicity was defined as Dutch, non-Dutch Western and non-Dutch 
non-Western. Maternal education defined by the highest completed education was classified as 
“higher” (higher vocational training or higher academic education), “secondary” (more than 3 
years general secondary school), and “primary” (lower vocational training or 3 years general 
secondary school). Maternal tobacco smoking was obtained in each trimester. On the basis of all 
three questionnaires, we defined the following categories: “never smoked,” “smoked until 
pregnancy was known,” and “continued throughout pregnancy”. Maternal alcohol use was 
categorized into “never drank in pregnancy”, “drank until pregnancy was known”, “continued to 
drink occasionally” and “continued to drink frequently”. Monthly household income at 
enrolment was categorized into >€ 2000 (more than modal income), €1200–€2000, and <€1200 
(below social security level). Maternal cognitive ability was assessed during the visit to the 
research centre at child’s age 5–7 years, with a computerized version of the Ravens Advanced 
Progressive Matrices (APM) Test, set I. 33 Set I consists of 12 items and has been shown to be a 
reliable and valid short form of the Raven’s Progressive Matrices to asses nonverbal intelligence. 
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34 Maternal psychiatric symptoms were assessed at 20 weeks of pregnancy and when the child 
was 3 years old using the Brief Symptom Inventory (BSI), a validated self-report questionnaire. 
35,36 At 20 weeks of pregnancy the complete 53-item questionnaire was assessed, which 
contained the following subscales: depression, anxiety, phobic anxiety, hostility, interpersonal 
sensitivity, paranoid ideation, somatization, obsessive-compulsive behaviour and psychoticism. 
We computed the Global Severity Index (GSI), 35 which we defined as the average item score 
across the two time points. Like NSAIDs, use of antidepressants (selective serotonin reuptake 
inhibitors) and benzodiazepines was also collected using a combination of questionnaires and 
pharmacy records. Further, as use of NSAIDs may co-occur with other medications, such as 
paracetamol (a.k.a., acetaminophen), we also collected this information from the same 
questionnaires (but not pharmacy records). 
 
Statistical analysis 
We estimated the associations between prenatal NSAIDs use and the following outcomes 
using separate linear regression models: maternal reports of somatic complaints and attention 
problems at 1.5, 3, and 5 years; teaching reports of attention problems at 6 years and non-verbal 
intelligence at 5 years. Models were adjusted for age and gender of the child; ethnicity, age, 
education and psychopathology of the mother; smoking and alcohol consumption during 
pregnancy; APM score of the mother; and exposure to paracetamol, antidepressants and 
benzodiazepines. For comparison, we also present unadjusted associations.   
We used NSAIDs use before pregnancy as a negative exposure and we used somatic 
complaints as a negative outcome in order to detect (residual) confounding. 20 It could be 
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possible that maternal reports of child behaviour may be biased via the personal characteristics 
of the respondent 37 and to account for this potential bias, we used teacher reports of attention 
problems and used a test-battery as a more objective measured outcome.  
The missing values on all confounders were below 20% except for the maternal cognitive 
ability score (22.4%). We accounted for missing information on the confounders by using the 
Markov Chain Monte Carlo imputation with predictive mean matching for continuous variables. 
38 Ten imputed datasets were generated using a fully conditional specified model. Analyses were 
performed separately on each completed dataset and thereafter combined to one pooled estimate. 
Children who did not have complete data on cognitive, emotional, or behavioural outcomes were 
more likely to have a lower birth weight and have mothers who were lower educated, younger, 
more likely to be non-Dutch, smoked more frequently, and had higher psychopathology 
symptom scores (Supplemental Table 1).  
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Results 
Characteristics of the study population 
The maternal and child characteristics stratified by prenatal NSAID exposure (most 
commonly ibuprofen, naproxen, diclofenac and aspirin) are presented in Table 1. Compared to 
mothers who did not use NSAIDs during pregnancy, mothers who used NSAIDs during 
pregnancy had a slightly higher body mass index and were more likely to smoke, use alcohol, 
and have psychopathology symptoms during pregnancy. Mothers who used NSAIDs before 
pregnancy were more likely to be non-Dutch, more likely to have a lower income and were less 
educated and had a lower cognitive ability score, as compared to the mothers who did not use 
NSAIDs.  
Insert Table 1 here 
NSAIDs exposure during pregnancy and maternal report of child attention problems  
Relative to mothers who did not use NSAIDs, mothers who used NSAIDs during pregnancy 
reported more attention problems in their children at ages 1.5, 3, and 5 years (Table 2). Adjusting 
for covariates slightly attenuated these estimates, but robust associations remained present at 
ages 1.5 years (mean difference in score: 0.27; 95% CI 0.07, 0.46) and 3 years (mean difference 
in score: 0.30; 95% CI 0.12, 0.48).  
Insert Table 2 here 
Investigation of residual confounding: pre-pregnancy NSAID use as a “negative exposure” 
Pre-pregnancy NSAID use was not strongly associated with maternally reported attention 
problems at ages 1.5, 3, and 5 years (Table 3).  
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Insert Table 3 here 
Investigation of residual confounding: somatic complaints as a “negative outcome” 
Prenatal NSAIDs exposure was not strongly associated with maternal report of somatic 
complaints (Table 4). For example, the adjusted mean difference in the somatic complaints score 
at age 3 years was 0.19 (95% CI -0.01, 0.38).  
Insert Table 4 here 
Investigation of reporting bias: teacher report of attention problems 
In contrast to maternal report of attention problems, no strong association was seen between 
prenatal NSAID exposure and teacher-reported attention problems at age 6 years (mean 
difference in attention score: -0.24; 95% CI -1.23, 0.76). In addition, no strong association was 
observed between prenatal NSAID exposure and teacher-reported somatic problems at 6 years 
(mean difference in somatic score: -0.05; 95CI -0.17, 0.08).  
Investigation of reporting bias: observed measure of non-verbal intelligence 
As shown in Table 5, relative to no exposure, prenatal NSAIDs exposure had little observed 
association with nonverbal intelligence (mean difference in IQ score: -0.07; 95% CI -1.67, 1.53). 
Adjusting for several potential confounders did not materially change the estimate (-0.32; 95% 
CI -1.82, 1.19).   
Insert Table 5 here 
14 
 
Discussion 
In the present study, mothers reported that children prenatally exposed to NSAIDs had a higher 
risk of attention problems (particularly at younger ages). Alongside our results regarding 
maternal reports of somatic complaints, maternal reports of pre-pregnancy NSAIDs use, teacher 
reports of attention problems and somatic complaints together and an observational measure of 
non-verbal intelligence, these findings altogether suggest that this apparent association can 
perhaps be largely explained by residual confounding by indication and measurement-related 
biases. Below we detail the insights gained from each of these additional analyses. 
 Confounding by indication is of particular concern in studying NSAID use during 
pregnancy, as the reasons for using these medications may affect child neurodevelopment and 
reporting of child neurodevelopment directly. As NSAIDs are often used to treat fever, pain and 
inflammation, it could be that these underlying conditions could be risk factors for 
neurodevelopmental problems. 39 While we were able to adjust for a rich set of measures on 
maternal psychopathology and other characteristics, apparent associations may still be explained 
by residual confounding. We used “negative” exposures and outcomes to indirectly assess 
whether confounding remained. As prenatal NSAID use and somatic complaints are likely 
confounded by the same sources of confounding as our primary research question, yet 
biologically we expect no direct effect, the fact that we found similar effect estimates (in the 
same direction) even after adjusting for measured confounders may suggests that the effect 
estimates may be biased. On the other hand, studying pre-pregnancy NSAID use and attention 
problems, which likewise we would biologically expect no direct effect, we did not find a robust 
association and the effect estimates were in the opposite direction. One possible reason for this is 
that the confounding structure may actually be different, as the set and severity of indications and 
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the choice for using NSAIDs pre-pregnancy may vary substantially from what occurs during 
pregnancy. In other words, pre-pregnancy NSAID use may not serve as a suitable “negative” 
exposure after all; there is some evidence of this in the descriptive statistics in Table 1, as 
mothers who reported pre-pregnancy NSAID use differed from mothers who reported used 
during pregnancy in terms of education, family income and other health behaviours during 
pregnancy.  
 Beyond confounding by indication, another possible limitation of studying 
maternally reported attention problems as an outcome is information bias. Namely, indications 
for treatment and other maternal characteristics may affect the measurement of the outcome 
while not directly affecting attention problems themselves. To assess this possibility, we 
considered outcomes reported by other sources, namely teacher-reported attention problems and 
a non-verbal cognitive functioning test performed at our research centre. We found no 
association between prenatal NSAIDs exposure and attention problems when the teachers 
reported about the child. The teachers’ perspective is valuable since teachers observe child 
behaviour in task-oriented situations where children are required to concentrate. Moreover, 
teachers can easily compare a particular child’s behaviour with that of a relatively large group of 
classmates of the same developmental level. 40 Therefore, our findings may suggest that mothers 
might over-report children’s attention problems, and that it is important to use a multi-informant 
approach as information of different informants may reflect variations in children’s behavior 
across diverse settings and relational circumstances.41-43 This finding is likewise corroborated by 
the null findings for the non-verbal intelligence score, although this score is measuring a 
different cognitive construct and thus can only be seen as indirect evidence of information bias.  
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However, there is a possibility that these associations of prenatal NSAIDs exposure on attention 
are transient being prominent in early childhood, as maternal NSAIDs use was not related to 
maternal reported attention problems as 5 years and our only available external reports (teacher 
reports; IQ score) were measured at 6 years.  
Strengths of the current study included its prospective design and use of multiple 
informants and multiple, repeated assessments. Some limitations of our study in particular merit 
consideration. First, while our analyses support that biases may explain much of the apparent 
association, our evidence only indirectly addresses the magnitude of bias. As such, it is possible 
that small (but perhaps clinically inconsequential) effects would remain even if such biases could 
be fully corrected for. Future studies may consider extending the set of analyses we have 
conducted here with more objective measurements of outcomes alongside richer assessments of 
women’s decisions to use NSAIDs prior to and during pregnancy. Second, as is common in birth 
cohort studies, some selective loss to follow-up among families from low socioeconomic status 
and non-Western origin occurred in Generation R. 21 While our study focused on exploring 
confounding and information biases, future work may consider the role of selection bias due to 
loss to follow-up. Further, in this study we did not examine the effects of different type of 
NSAIDs, dose dependent effects and trimester-specific effects, as the information that we 
collected from the questionnaires was very general. However, NSAIDS all involve COX- 
inhibition, followed by suppression of prostaglandin synthesis in the brain, 11 and thus type-
specific effects would be unlikely. Further, somatic complaints were asked using the CBCL, this 
subscale specifically refers to physical problems (e.g. headaches, nausea and stomach aches) 
without a known medical cause; and thus we cannot exclude that part of these somatic 
complaints are due to underlying psychopathology. Finally, the analyses were performed using a 
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variety of measures at different ages in slightly different samples; differences in the study 
populations included in each analysis or differences in their susceptibility to bias due to loss to 
follow up may theoretically explain some results. and thus, we need to be cautious in the 
interpretations of our findings.  
In conclusion, by controlling for several potential confounders, using outcomes measured 
repeatedly and across different informants, studying pre-pregnancy exposure, and using proposed 
negative outcomes, this study provides evidence that the observed associations between prenatal 
exposure to NSAIDs and child attention problems in this study and possibly previous studies 
likely indicate null or small (i.e. near-null) causal effect.  
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Table 1.Maternal and child characteristics stratified by prenatal NSAID exposure 
SD: standard deviation, BMI: body mass index 
 
 
 Prenatal NSAID exposure  
 No use  
(n = 5117) 
Use before pregnancy 
 (n = 1286) 
Use during pregnancy  
(n = 473)  
Child characteristics     
Gender (% girls) 50.15 49.92  50.32  
Birth weight in grams, mean (SD) 3409.43(575.78) 3416.84 (563.64) 3377.08 (535.00)  
Gestational age at birth in weeks, mean 
(SD) 
39.84 (1.81) 39.80 (1.91)  39.72 (1.65)  
Apgar score at 5 min after birth, mean 
(SD) 
9.62 (0.76) 9.58 (0.90)  9.60 (0.78)  
Maternal characteristics     
Age in years, mean (SD)  30.29 (5.11) 29.69 (5.17)  30.35 (4.83)  
Ethnicity (%)      
  Dutch 54.06 45.75 58.10  
  Non-Dutch Western 9.00 6.90 8.71  
  Non-Dutch non-Western 36.94 47.35 33.19  
Education  (%)      
  Higher 47.65 33.68 42.85  
  Secondary 42.70 53.27 46.83  
  Primary 9.65 13.05 10.32  
Family income (%)     
  >2000 €/month 62.28 51.95 60.42  
  1200-2000 €/month 18.36 22.93 18.67  
  <1200 €/month 19.36 25.12 20.91  
BMI in kg/m2, mean (SD)  24.56 (4.34) 25.43 (4.78)  25.03 (4.49)  
Smoking during pregnancy (%)      
  Never  75.62 70.25 66.13  
  Until pregnancy was known 8.69 8.98 12.60  
  Continued throughout pregnancy 15.69 20.77 21.27  
Alcohol use during pregnancy (%)      
  Never 45.35 53.00 39.64  
  Until pregnancy was known 13.22 12.16 16.03  
  Continued occasionally 
  Continued frequently 
33.10 
8.33 
29.41 
5.43 
33.15 
11.18 
 
Psychopathology symptoms, mean (SD)  0.28 (0.36) 0.34 (0.41)  0.35 (0.41)  
Cognitive ability score, mean (SD)  96.17 (15.18) 92.68 (15.59)  95.75 (14.77)  
Co-medication (%)     
 Antidepressants 1.04 1.6 1.9  
 Benzodiazepines 0.86 2.6 4.0  
 Paracetamol 21.6 25.0 44.0  
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Table 2. The association of exposure to NSAIDs during pregnancy and offspring attention problems reported by mothers  
Attention Problems N Exposed/ N Non-
exposed 
Unadjusted Mean Difference 
in Attention Problems Score 
 Adjusted Mean Difference in 
Attention Problems Score † 
       
Maternal report at 1.5 yrs. 336/4054 0.31 (0.11, 0.51)  0.27 (0.07, 0.46) 
Maternal report at 3 yrs.  310/3800 0.35 (0.16, 0.53)  0.30 (0.12, 0.48) 
Maternal report at 5 yrs. 372/4872 0.13 (-0.06, 0.31)  0.05 (-0.13, 0.23) 
       
† Adjusted model, covariates: age and gender of the child, ethnicity, age, education and psychopathology of the mother, smoking and alcohol 
consumption during pregnancy, and APM score of the mother, prenatal exposure to paracetamol, antidepressants and benzodiazepines. 
 
 
Table 3. Negative exposure: the association of exposure to NSAIDs before pregnancy and offspring attention problems reported by mothers 
Attention Problems N Exposed/ N Non-
exposed 
Unadjusted Mean Difference 
in Attention Problems Score 
 Adjusted Mean Difference in 
Attention Problems Score † 
       
Maternal report at 1.5 yrs. 701/3689 0.04 (-0.11, 0.18)  -0.08 (-0.22, 0.06) 
Maternal report at 3 yrs.  679/3431 0.08 (-0.05, 0.21)  -0.06 (-0.19, 0.07) 
Maternal report at 5 yrs. 925/4319 0.05 (-0.07, 0.18)  -0.08 (-0.20, 0.04) 
       
† Adjusted model, covariates: age and gender of the child, ethnicity, age, education and psychopathology of the mother, smoking and alcohol 
consumption during pregnancy, and APM score of the mother, prenatal exposure to paracetamol, antidepressants and benzodiazepines. 
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Table 4. Negative outcome: The association of exposure to NSAIDs during pregnancy and offspring somatic problems reported by mothers 
Somatic complaints N Exposed/ N Non-
exposed 
Unadjusted Mean Difference 
in Somatic Complaints Score 
 Adjusted Mean Difference in 
Somatic Complaints Score † 
       
Maternal report at 1.5 yrs. 332/4024 0.12 (-0.05, 0.29)  0.09 (-0.09, 0.26) 
Maternal report at 3 yrs.  310/3804 0.23 (0.04, 0.42)  0.19 (-0.01, 0.38) 
Maternal report at 5 yrs. 370/4586 0.24 (0.05, 0.44)  0.13 (-0.06, 0.32) 
       
† Adjusted model, covariates: age and gender of the child, ethnicity, age, education and psychopathology of the mother, smoking and alcohol 
consumption during pregnancy, and APM score of the mother, prenatal exposure to paracetamol, antidepressants and benzodiazepines. 
 
 
Table 5. Reporting bias: The association of exposure to NSAIDs during pregnancy and offspring attention problems reported by teachers and non-
verbal IQ assessed by a research assistant 
Independent observations N Exposed/ N Non-
exposed 
Unadjusted Mean Difference 
in Outcome Score 
 Adjusted Mean Difference in 
Outcome Score † 
     
       
Teacher report of attention 
problems at 6 yrs. 
276/3511 -0.09 (-1.16, 0.98)  -0.24 (-1.23, 0.76) 
Teacher report of somatic 
problems at 6 yrs. 
274/3499 -0.04 (-0.16, 0.09)  -0.05 (-0.17, 0.08) 
Non-verbal IQ assessment 362/4729 -0.07 (-1.67, 1.53)  -0.32 (-1.82, 1.19) 
       
†Adjusted model, covariates: age and gender of the child, ethnicity, age, education and psychopathology of the mother, smoking and alcohol 
consumption during pregnancy, and APM score of the mother, prenatal exposure to paracetamol, antidepressants and benzodiazepines. 
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